Polar Capital’s Achillion Pharmaceuticals ACHN Stock Holding History

Polar Capital’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-18,707	Closed	-$229K	–	304
2014 Q4	$229K	Buy	+18,707	New	+$228K	﹤0.01%	271
2014 Q1	–	Sell	-15,121	Closed	-$50K	–	284
2013 Q4	$50K	Buy	+15,121	New	+$43.9K	﹤0.01%	267

Other funds holding ACHN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Polar Capital's ACHN Position: Q1 2015 in Review

Polar Capital sold out of Achillion Pharmaceuticals (ACHN) in Q1 2015, closing a stake of 18,707 shares — an estimated $229K sold.

Polar Capital first reported a position in ACHN in Q4 2013 and held it in 2 quarters. The position peaked at $229K in Q4 2014. 173 funds tracked by Wall St. Rank hold ACHN as of Q1 2015.

Polar Capital reported no remaining Achillion Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Polar Capital sold 18,707 Achillion Pharmaceuticals shares in Q1 2015, an estimated $229K.
Polar Capital first reported a position in Achillion Pharmaceuticals in Q4 2013 and held it in 2 quarters.
Polar Capital's Achillion Pharmaceuticals position peaked at $229K in Q4 2014.
173 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2015.

Based on Polar Capital's 13F filing for Q1 2015, filed 15 May 2015.